Evaluation of the Association between Androgen Receptor and AURKA and Its Prognostic Value in Gastric Cancer

Abstract

Background: It is well-known that Aurora kinase A (AURKA) shows oncogenic properties in various tumor types including gastric cancer (GC). Moreover, previous studies have demonstrated that AURKA has a specific androgen receptor (AR) binding site in its promoter; thus, it could be regulated by AR. Since it has been shown that AR overexpresses in gastric cancer (GC) as a male-predominant tumor, the goal of this study was to evaluate the association between AR and AURKA and its prognostic value in GC patients. Materials and Methods: We assessed the expression profile of AURKA in 60 fresh GC and adjacent non-tumor tissues and 50 normal gastric specimen by qRT-PCR, and investigated the association of AURKA expression with clinicopathological features. Furthermore, we evaluated possible correlation between AURKA and AR to elucidate a novel prognostic marker using Kaplan-Meier method and Cox regression model. Conclusion: Among GC patients, 65% (39/60) overexpressed AURKA relative to normal gastric tissues. AURKA overexpression was significantly correlated with the AR overexpression in GC patients. Although AURKA expression alone was not remarkably associated with poor outcome, we provided some evidence that combined evaluation of AURKA and AR expression could independently predict survival of GC patients adjusted for other variables (HR=1.7, CI=1.314-3.833 p=0.042). Conclusion: These results indicate that AR and AURKA may crosstalk to promote GC progression. Our findings have clinical importance because they suggest simultaneous assessment of AURKA and AR expression as a novel potential prognostic marker.

Tanshinone Inhibits NSCLC by Downregulating AURKA Through Let-7a-5p

“…For example, Chen et al (2017) suggested that AURKA was reactivated in metastasis of irradiated hepatocellular carcinoma (HCC) through facilitating epithelial–mesenchymal transitions (EMTs) and cancer stem cell (CSC) properties. Soleymani Fard et al (2019) showed that upregulation of AURKA might promote gastric cancer progression. de Jong et al (2019) indicated that a high expression of AURKA correlated with cell cycle progression during chondrosarcoma cell survival.…”

Long Non-Coding RNA PCED1B-AS1 Promotes the Progression of Clear Cell Renal Cell Carcinoma Through miR-484/ZEB1 Axis

“…30,31 ZEB1 is abnormally expressed in a variety of cancers, such as colorectal cancer, lung cancer, breast cancer, and gastric cancer, and it is involved in the proliferation, migration and invasion of cancer cells and is considered to have cancer-promoting functions. [32][33][34][35][36] For example, lncRNA TMPO-AS1 facilitates the proliferation, migration, and invasion of cervical cancer cells by modulating the miR-143-3p/ZEB1 axis. 37 In this study, we predicted and verified that miR-484 was able to target ZEB1, and that ZEB1 expression in ccRCC patient tissues was positively regulated by PCED1B-AS1.…”

Kinase inhibitor screening reveals aurora‐a kinase is a potential therapeutic and prognostic biomarker of gastric cancer

“…Despite the relevant importance of all kinase targets mentioned before, AURKA has attracted special attention for being an emergent target in gastric cancer therapy and prognosis evaluation. 40 Numerous in vitro, in vivo, and tissue sample studies have shown the involvement of AURKA in gastric cancer development through different types of intracellular pathways. 30,41,42 Several studies also have shown the significant association of AURKA gene F I G U R E 5 Survival fraction of gastric cancer patients enrolled in this study.…”